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Background: Open bypass is the gold standard for treatment of mesenteric ischemia. With the reﬁnement of endovascular
therapy, visceral stenting is an attractive minimally invasive alternative, but the data are limited and which vessel responds
best to stenting has not been addressed. This study compares the outcomes of superior mesenteric artery (SMA) and celiac
artery (CA) stenting.
Methods: All consecutive patients who underwent visceral stenting between January 2002 and May 2009 were reviewed.
Standard statistical analyses, including Kaplan-Meier tests, were performed. Primary patency was deﬁned as peak systolic
velocities <350 cm/s for CAs and <450 cm/s for SMAs. Clinical patency was maintenance of either primary patency or
the absence of recurrent symptoms. At arteriography, stenosis $70% was considered a loss of primary patency.
Results: One hundred twenty-one patients received 140 visceral stents in the SMA (n [ 92; 65.7%), the CA (n [ 40;
28.6%), and the inferior mesenteric artery (n[ 8; 5.7%). Twenty-nine stents were placed in men (20.7%) and 111 stents
were placed in women (79.3%) with a mean age of 72.9 years (range, 20.5-93.9). The combined SMA/CA stent mean
follow-up was 12.8 months. Technical success was 100% for all. Overall 30-day morbidity and mortality rates were 14%
and 0.8%, respectively. One-year primary patency was signiﬁcantly higher for SMA than for CA stents: 55% versus 18%,
respectively (P < .0001). Six-month clinical patency was 86% for the SMA and 67% for the CA (P < .005). Loss of CA
primary patency was associated with stent diameter <6 mm (P[ .042) and age <50 years (two patients; P[ .038). These
factors did not correlate with loss of primary patency for SMA. Overall freedom from bypass was 93% at 4 years.
Conclusions: Visceral stenting has an exceptionally high technical success rate with low procedural morbidity and
mortality. Clinical primary patency and primary patency were signiﬁcantly higher for the SMA group than for the CA
group. Our data suggest that CA atherosclerotic lesions do not respond well to endovascular stenting, bringing into
question its clinical utility. (J Vasc Surg 2013;57:1062-6.)Atherosclerosis, leading to stenosis and occlusion of the
mesenteric arteries, is considered the leading cause of
chronic mesenteric ischemia, which can lead to bowel
necrosis and possibly death.1 Open surgery has been the
gold standard in the treatment of chronic mesenteric
ischemia since its ﬁrst success in 1958.2 With the introduc-
tion of endovascular procedures such as percutaneous
transluminal angioplasty and stenting, the trend is shifting
to more minimally invasive approaches. The literature
suggests that symptomatic resolution is similar for open
and endovascular revascularization.3 The use of percuta-
neous transluminal angioplasty and stent placement has
been shown to lead to favorable outcomes with primary
and primary-assisted patency at 6 months ranging from
78.2 to 99%.4,5 However, the issue of which vesselthe Division of Vascular Surgery, Eastern Virginia Medical School.
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2responds best to stenting has not been fully addressed.
This study compares the outcomes of superior mesenteric
artery (SMA) and celiac artery (CA) stenting.
METHODS
This is a retrospective review of all consecutive patients
who underwent visceral stenting for visceral stenosis with
the exclusion of vessel occlusions between January 2002
and May 2009. Records were reviewed for demographics,
risk factors, preoperative and postoperative symptoms,
and procedural and follow-up data including duplex ultra-
sound (DUS) ﬁndings. c2 analysis was performed to iden-
tify factors that would impact stent patency. Kaplan-Meier
estimates were used to determine patency and survival,
with statistical signiﬁcance based on log-rank. P < .05
was used to determine signiﬁcance. All statistical analysis
was performed using XLSTAT 1 (Addinsoft SARL, Ander-
nach, Germany).
Mesenteric procedures were performed under mod-
erate sedation in our endovascular suite. Because we
performed a retrospective review, the speciﬁcs of the proce-
dure were at the discretion of the operating surgeon.
Details of the procedure including sheaths, catheters, and
type of stent varied based on the attending surgeon, but
all visceral stents were balloon expandable.
Visceral DUS was performed at 1, 6, and 12 months of
follow-up. Mesenteric stents were considered free of
in-stent restenosis if peak systolic velocity was <350 cm/s
Table I. Demographic and risk factor data for visceral stentinga
Total CA/SMA (n ¼ 132) CA (n ¼ 40) SMA (n ¼ 92) P value
Demographics
Women 108 (82%) 32 (79%) 76 (83%) .46
Men 24 (18%) 8 (21%) 16 (18%) .46
Age 73 (21-94) 74 (46-90) 72 (21-94)
Risk factor
Hypertension 106 (80%) 32 (80%) 74 (80%) .98
Hyperlipidemia 80 (61%) 27 (67%) 53 (58%) .31
Diabetes 50 (38%) 19 (47%) 31 (34%) .16
Tobacco use 107 (81%) 27 (67%) 80 (87%) .59
Cerebral vascular disease 33 (25%) 8 (20%) 25 (27%) .35
Coronary artery disease 72 (55%) 26 (65%) 46 (50%) .12
Congestive heart failure 16 (12%) 5 (12%) 11 (12%) .95
Peripheral vascular disease 77 (58%) 24 (60%) 53 (58%) .85
Chronic obstructive pulmonary disease 35 (26%) 9 (22%) 26 (28%) .46
End-stage renal disease 4 (3%) 1 (3%) 3 (3%) .92
Chronic renal insufﬁciencyb 11 (8%) 3 (7%) 8 (9%) .65
CA, Celiac artery; SMA, superior mesenteric artery.
aValues are given as the number of patients (%) or mean (range).
bDeﬁned as stage 2 or worse chronic kidney disease.
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nally validated in our peripheral vascular laboratory and
correlated with an angiographic ﬁnding of $70% stent
restenosis. Absence of any duplex or angiographic evidence
of stenosis deﬁned primary patency. Clinical patency was
deﬁned as either the absence of symptoms or maintenance
of primary patency.
Periprocedural morbidity and mortality were deﬁned as
any adverse event occurring within 30 days of the proce-
dure regardless of relation to the procedure. Late mortality
was veriﬁed by the Social Security database. This study was
approved by the Eastern Virginia Medical School institu-
tional review board.
RESULTS
Between January 2002 and May 2009, 121 patients,
all with multivessel disease, received 140 visceral stents.
Access was the femoral artery in 84% of patients and the
left brachial artery in 15% of patients. If the CA, SMA,
and inferior mesenteric artery (IMA) are combined, 29
(20.7%) stents were placed in men and 111 (79.3%) stents
in women, with an overall mean age of 72.9 years (range,
20.5-93.9). Medical comorbidities included hypertension
(80.7%), hyperlipidemia (61.4%), tobacco use (87.9%),
coronary artery disease (55%), and peripheral vascular
disease (57.1%) (Table I).
There was no signiﬁcant difference in demographics
between patients who received CA stents and those who
received SMA stents (Table I). All patients underwent pre-
procedural DUS to diagnose visceral stenosis, which was
conﬁrmed with angiography.
Anatomic location of the mesenteric stents included
the SMA (n ¼ 92 stents; 65.7%), CA (n ¼ 40 stents;
28.6%), and IMA (n ¼ 8 stents; 5.7%). All isolated CA
stents (n ¼ 22) were placed in individuals with multivessel
visceral stenosis, with the CA presenting with the moresevere stenosis on angiography. Nineteen patients had
two vessels stented: 18 patients had both CA and SMA
stents, and one patient had both SMA and IMA stents.
Because of the small numbers, IMA stents were not
included in the comparisons of outcomes.
All visceral stents were placed in symptomatic patients
with abdominal pain. Other common symptoms included
weight loss (55%) and food fear (20%) (Table II). There
was no signiﬁcant difference in symptoms between patients
who received CA stents and those who received SMA
stents (Table II).
Technical success was 100% as determined by angio-
graphic evidence of <30% residual stenosis. The only
signiﬁcant procedural difference between the SMA and
CA groups was mean stent length (SMA ¼ 20.35 mm vs
CA ¼ 16.63 mm; P < .05). One patient in the CA group
died of a gastrointestinal bleed on postoperative day 29,
yielding an overall 30-day periprocedural mortality rate of
0.8%. Overall 30-day procedure-related morbidity rate
was 14%, with a majority of complications being access
related (three pseudoaneurysms, two femoral hematomas,
one brachial artery repair), renal (one contrast-induced
nephropathy and one acute renal failure), or gastrointes-
tinal (one upper bleed caused by esophagitis and two lower
bleeds caused by colonic ischemia), with no difference
between the two groups.
Overall mean follow-up was 12.8 months, with mean
follow-up periods of 13.1 months (range, 0.3-53.9) for
the SMA group and 11.9 months (range, 0.2-48.8) for
the CA group. The overall clinical patency rate was 63%
at 1 year. The SMA stent group had a signiﬁcantly higher
primary patency than the CA stent group, with a 1-year
primary patency of 55% for the SMA stents and only 18%
for the CA stents (P < .0001) (Fig 1). The SMA stents
again demonstrated a statistically signiﬁcant advantage in
clinical patency when compared with CA stents, with
Table II. Symptomatology and laboratory values of
patients who received celiac artery and superior
mesenteric artery stentsa
Symptom
Total CA/SMA
(n ¼ 132)
CA
(n ¼ 40)
SMA
(n ¼ 92)
P
value
Weight loss 73 (55%) 20 (50%) 43 (47%) .78
Food fear 27 (20%) 9 (22%) 18 (47%) .75
Nausea or emesis 58 (44%) 21 (52%) 37 (40%) .22
Diarrhea 58 (44%) 18 (45%) 40 (43%) .91
Hematochezia 16 (12%) 7 (17%) 9 (10%) .35
Mean preoperative
creatinine level
(mg/dL)
1.34 1.38 1.32 .79
SMA, Superior mesenteric artery; CA, celiac artery.
aValues are given as the number of patients (%) unless otherwise noted.
Fig 1. Kaplan-Meier curves for primary patency results for celiac
artery versus superior mesenteric artery (SMA) stenting.
Fig 2. Kaplan-Meier curves for clinical patency results for celiac
artery versus superior mesenteric artery (SMA) stenting.
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versus 67% for the CA group (P < .005) (Fig 2).
Thirty-two (34.8%) SMA stents and 12 (30%) CA
stents required reintervention. Two CA stents required
restenting; the remaining reinterventions involved angio-
plasty, with one cutting balloon angioplasty. Nine SMA
stents required restenting; the remaining reinterventions
were balloon angioplasties, 10 of which were cutting
balloon angioplasties. Average time to reintervention was
5 months longer in the SMA group (14.1 months) than
in the CA group (9.1 months) (P < .043).
The overall survival of all patients at 1 year was 85%,
with no additional gastrointestinal-related deaths and no
difference between groups. Overall freedom from reinter-
vention at 1year was 54%, and at 4 years, 18%. Overall
freedom from open surgical bypass was 93% at 4 years,
with one CA bypass at 13.2months and three SMA bypasses
at a mean of 11.9 months (range, 0-28.9). The 1-year
survival free from symptom recurrence for the SMA group
was 63% versus 53% for the CA group (P ¼ .07)
Further analysis was performed to determine if any risk
factor correlated with in-stent restenosis. CA artery in-stent
restenosis was associated with congestive heart failure,
coronary artery disease, hypertension, chronic renal insuf-ﬁciency, age <50, and stent diameter <6 mm (P < .05
for all). No comorbidity or procedural factors were found
to signiﬁcantly impact SMA in-stent restenosis.
Lastly, a comparison of combined two-vessel stenting
of the CA and SMA with single CA and SMA stenting
revealed no signiﬁcant difference in rates of in-stent reste-
nosis and no difference in survival free from symptom
recurrence.DISCUSSION
The ﬁrst described successful use of percutaneous
angioplasty to treat mesenteric ischemia was in 1980.7
Further advancements in the treatment of CMI, princi-
pally percutaneous transluminal angioplasty and stenting,
have changed the course of treatment. Endovascular
treatment provides a potential improvement in the 5%-
30% morbidity rate and 2%-12% mortality rate of open
repair.3,8-12 Our low morbidity and mortality rates and
high technical success rate (100%) are similar to those in
the literature.13-22 But controversy still exists as to the
comparison of open and endovascular mesenteric revascu-
larization, with some citing the superiority of open repair
based on superior durability.23 Yet the concept and the
execution of visceral stenting have evolved to make it
a beneﬁcial therapy in high-risk patients not candidates
for open revascularization. Unfortunately, the outcome
of CA stenting versus that of SMA stenting has yet to
be fully examined.
A major ﬁnding in our study is the great discrepancy in
clinical patency and freedom from in-stent restenosis/
primary patency between CA stenting and SMA stenting.
The reason for the difference requires further investigation,
but our proposed hypothesis is that the CA is in a poor
anatomic location and the dynamic forces of respiration
combined with the ﬁxed ligament attachments of the dia-
phragm potentially inﬂuence the results of CA angioplasty
and stenting.
On examination of the CA group, stents with a diame-
ter <6 mm were signiﬁcantly more likely to lose primary
patency earlier than larger-caliber stents. This could be
due to the relationship between radius and resistance to
JOURNAL OF VASCULAR SURGERY
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increases fourfold. A diameter of 6 mm may be a critical
threshold below which stents should not be deployed in
the CA, if any endovascular treatment must be used. All
stents were balloon expandable, but it would be interesting
to see if use of nitinol or covered stents improved results in
the CA.
It has been suggested that open operations for chronic
mesenteric ischemia have an improved long-term success
rate when bypasses to both the CA and SMA are per-
formed.24,25 Recent data also suggest that this may be
true as well for endovascular management.22 But the liter-
ature reports mixed results for single- versus two-vessel
stenting.1,22,26 We did compare the subgroup of patients
who had combined SMA and CA stenting with the
subgroup that had single mesenteric stenting and we found
no signiﬁcant difference in the rates of in-stent restenosis
(as deﬁned under Methods) or survival free from symptom
recurrence, although our patient numbers were smaller.
Currently, there is no consensus on the number of vessels
requiring endovascular treatment in patients with multives-
sel mesenteric disease.
Limitations to our study include the retrospective
nature of the study, the relatively small number of combined
SMA/CA stenting procedures, and the use of DUS to
diagnose in-stent restenosis. DUS still has an undeﬁned
role in diagnosing in-stent restenosis. Using native vessel
criteria for reintervention in in-stent restenosis, Morvay
et al found that intervention based on ultrasound ﬁndings
did not improve patency outcomes or prevent recurrence
of symptoms.27 Recently, in a hypothesis-seeking study,
Mitchell et al concluded that DUS criteria for native SMA
stenosis cannot be applied to stented SMA stenosis.28 Early
in our experience, angiogramswould be performed based on
the lower nonvalidated velocity criteria to conﬁrm the
diagnosis of in-stent restenosis. These were considered as
reinterventions for this study, possibly lowering the patency
rates.
On the basis of a recent internal validation study in our
vascular laboratory, we are now using higher peak systolic
velocity (peak systolic velocity >350 cm/s for CAs and
>450 cm/s for SMAs) before proceeding with a visceral
angiogram for suspected in-stent restenosis.6CONCLUSIONS
In comparison to open repair, there has been a dramatic
increase in the use of percutaneous transluminal angio-
plasty and stenting for the treatment of chronic mesenteric
ischemia in high-risk patients. The literature has not
compared CA stenting with SMA stenting. Which vessels
to consider for stenting is an important concept, as our
study shows that regardless of the number of vessels endo-
revascularized, CA stenting has a very high in-stent reste-
nosis rate, signiﬁcantly poorer clinical patency rates, and
a trend toward a higher reintervention rate. This retrospec-
tive study brings into question the utility of stenting the
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